The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Impact of ABL kinase domain mutations on the outcome of patients with chronic myeloid leukemia (CML).
Kendra Lynn Sweet
No relevant relationships to disclose
Rami S. Komrokji
No relevant relationships to disclose
Najla Al Ali
No relevant relationships to disclose
Robert M. Crescentini
No relevant relationships to disclose
Gelenis Domingo
No relevant relationships to disclose
Julio C. Chavez
No relevant relationships to disclose
Samir Dalia
No relevant relationships to disclose
Sara Tinsley
No relevant relationships to disclose
Jeffery Lancet
No relevant relationships to disclose
Ling Zhang
No relevant relationships to disclose
Javier Pinilla-Ibarz
No relevant relationships to disclose